JP2019536793A5 - - Google Patents

Download PDF

Info

Publication number
JP2019536793A5
JP2019536793A5 JP2019529525A JP2019529525A JP2019536793A5 JP 2019536793 A5 JP2019536793 A5 JP 2019536793A5 JP 2019529525 A JP2019529525 A JP 2019529525A JP 2019529525 A JP2019529525 A JP 2019529525A JP 2019536793 A5 JP2019536793 A5 JP 2019536793A5
Authority
JP
Japan
Prior art keywords
antibody
formulation
subject
tumor
exogenous polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019529525A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019536793A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/064299 external-priority patent/WO2018102740A1/en
Publication of JP2019536793A publication Critical patent/JP2019536793A/ja
Publication of JP2019536793A5 publication Critical patent/JP2019536793A5/ja
Pending legal-status Critical Current

Links

JP2019529525A 2016-12-02 2017-12-01 固形腫瘍に浸透させるための細胞系に関連する組成物および方法 Pending JP2019536793A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662429275P 2016-12-02 2016-12-02
US62/429,275 2016-12-02
PCT/US2017/064299 WO2018102740A1 (en) 2016-12-02 2017-12-01 Compositions and methods related to cell systems for penetrating solid tumors

Publications (2)

Publication Number Publication Date
JP2019536793A JP2019536793A (ja) 2019-12-19
JP2019536793A5 true JP2019536793A5 (enExample) 2021-01-21

Family

ID=60937855

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019529525A Pending JP2019536793A (ja) 2016-12-02 2017-12-01 固形腫瘍に浸透させるための細胞系に関連する組成物および方法

Country Status (13)

Country Link
US (2) US20180153989A1 (enExample)
EP (1) EP3548050A1 (enExample)
JP (1) JP2019536793A (enExample)
KR (1) KR20190091497A (enExample)
CN (1) CN110225756A (enExample)
AU (1) AU2017366706A1 (enExample)
BR (1) BR112019011138A2 (enExample)
CA (1) CA3045331A1 (enExample)
IL (1) IL266940A (enExample)
MX (1) MX2019006423A (enExample)
RU (1) RU2019120400A (enExample)
SG (1) SG10202105661TA (enExample)
WO (1) WO2018102740A1 (enExample)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3071515A2 (en) 2013-11-18 2016-09-28 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
EP3583946A1 (en) 2014-04-01 2019-12-25 Rubius Therapeutics, Inc. Enucleated hematopoietic cells comprising an exogenous antigen
PT3402491T (pt) 2016-01-11 2022-03-03 Rubius Therapeutics Inc Composições e métodos relacionados com sistemas celulares terapêuticos multimodais para indicações de cancro
PL3469361T3 (pl) 2016-06-10 2025-02-03 Gadeta B.V. Nowy sposób identyfikacji łańcuchów receptora limfocytu t delta (lub limfocytu t gamma) lub części tych łańcuchów, które pośredniczą w odpowiedzi przeciwnowotworowej lub przeciwzakaźnej
CA3052142A1 (en) 2017-02-17 2018-08-23 Rubius Therapeutics, Inc. Functionalized erythroid cells
US10960071B2 (en) 2017-08-07 2021-03-30 The Regents Of The University Of California Platform for generating safe cell therapeutics
WO2019032628A1 (en) 2017-08-07 2019-02-14 The Regents Of The University Of California GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS
EP3703751A2 (en) * 2017-11-03 2020-09-09 Rubius Therapeutics, Inc. Compositions and methods related to therapeutic cell systems for tumor growth inhibition
US12089930B2 (en) 2018-03-05 2024-09-17 Marquette University Method and apparatus for non-invasive hemoglobin level prediction
MX2020009359A (es) * 2018-03-08 2021-01-29 Rubius Therapeutics Inc Sistemas de celulas terapeuticas y metodos para el tratamiento de cancer y enfermedades infecciosas.
WO2020028134A1 (en) * 2018-07-30 2020-02-06 Fred Hutchinson Cancer Research Center Methods and compositions for treating cancer
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
US11166996B2 (en) 2018-12-12 2021-11-09 Flagship Pioneering Innovations V, Inc. Anellovirus compositions and methods of use
SG11202107206RA (en) 2019-01-18 2021-08-30 Flagship Pioneering Inc Trem compositions and uses thereof
IL321343A (en) * 2019-01-28 2025-08-01 Sanofi Sa Methods of treating multiple myeloma
JP2022523794A (ja) 2019-03-04 2022-04-26 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー 環状ポリリボヌクレオチド及びその医薬組成物
EP3946466A2 (en) 2019-03-25 2022-02-09 Flagship Pioneering Innovations VI, LLC Compositions comprising modified circular polyribonucleotides and uses thereof
US20220228147A1 (en) 2019-05-31 2022-07-21 Flagship Pioneering, Inc. Uses of trem compositions to modulate trna pools
AU2020292427A1 (en) 2019-06-14 2022-01-06 Flagship Pioneering Innovations Vi, Llc Circular RNAs for cellular therapy
EP3986469A1 (en) 2019-06-19 2022-04-27 Flagship Pioneering Innovations VI, LLC Compositions comprising circular polyribonucleotides for protein modulation and uses thereof
US20220330541A1 (en) 2019-09-05 2022-10-20 Hemanext Inc. Methods for the Preservation of Reagent Red Blood Cells Using Carbon Monoxide
WO2021068971A1 (en) * 2019-10-12 2021-04-15 Bio-Thera Solutions, Ltd. Anti-cd20 antibody formulation and use of anti-cd20 antibody for treatment of cd20 positive diseases
EP4055169A1 (en) 2019-11-04 2022-09-14 Flagship Pioneering, Inc. Methods of modifying a nucleic acid sequence
JP2023500116A (ja) 2019-11-04 2023-01-04 フラッグシップ パイオニアリング， インコーポレイテッド ｃｏｎ－希少コドンのためのＴＲＥＭ組成物及び関連する使用
US20230104113A1 (en) 2020-01-29 2023-04-06 Flagship Pioneering Innovations Vi, Llc Delivery of compositions comprising circular polyribonucleotides
WO2021155175A1 (en) 2020-01-29 2021-08-05 Flagship Pioneering Innovations Vi, Llc Compositions for translation and methods of use thereof
EP4096715A1 (en) 2020-01-29 2022-12-07 Flagship Pioneering Innovations VI, LLC Compositions comprising linear polyribonucleotides for protein modulation and uses thereof
TW202206097A (zh) 2020-05-20 2022-02-16 美商旗艦先鋒創新有限責任公司 冠狀病毒抗原組成物及其用途
EP4153223A1 (en) 2020-05-20 2023-03-29 Flagship Pioneering Innovations VI, LLC Immunogenic compositions and uses thereof
EP4153152A1 (en) 2020-05-20 2023-03-29 Flagship Pioneering Innovations VI, LLC Compositions and methods for producing human polyclonal antibodies
CA3182026A1 (en) 2020-05-29 2021-12-02 Flagship Pioneering Innovations Vi, Llc. Trem compositions and methods relating thereto
IL298539A (en) 2020-05-29 2023-01-01 Flagship Pioneering Innovations Vi Llc Trem compositions and methods relating thereto
WO2021262799A1 (en) 2020-06-23 2021-12-30 Flagship Pioneering, Inc. Anti-viral compounds and methods of using same
EP4208196A1 (en) 2020-09-03 2023-07-12 Flagship Pioneering Innovations VI, LLC Immunogenic compositions and uses thereof
BR112023012377A2 (pt) 2020-12-23 2023-10-24 Flagship Pioneering Innovations Vi Llc Composições de trems modificadas e usos das mesmas
WO2022183057A1 (en) * 2021-02-26 2022-09-01 Cytonus Therapeutics, Inc. Compositions and methods for therapeutic delivery
CA3213636A1 (en) * 2021-03-18 2022-09-22 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
US20220325287A1 (en) 2021-03-31 2022-10-13 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
WO2022214707A1 (en) * 2021-04-09 2022-10-13 Gadeta B.V. Cellular reporter and methods of using the same
EP4377457A1 (en) 2021-07-26 2024-06-05 Flagship Pioneering Innovations VI, LLC Trem compositions and uses thereof
DK4271818T3 (da) 2021-09-17 2024-11-04 Flagship Pioneering Innovations Vi Llc Sammensætninger og fremgangsmåder til fremstilling af cirkulære polyribonukleotider
US20240417714A1 (en) 2021-10-18 2024-12-19 Flagship Pioneering Innovations Vi, Llc Compositions and methods for purifying polyribonucleotides
IL312965A (en) 2021-11-24 2024-07-01 Flagship Pioneering Innovations Vi Llc Immunogenic compositions and their uses
CN118900845A (zh) 2021-11-24 2024-11-05 旗舰创业创新六公司 冠状病毒免疫原组合物及其用途
CA3238370A1 (en) 2021-11-24 2023-06-01 Flagship Pioneering Innovations Vi, Llc Varicella-zoster virus immunogen compositions and their uses
AU2022417517A1 (en) 2021-12-22 2024-06-27 Flagship Pioneering Innovations Vi, Llc Compositions and methods for purifying polyribonucleotides
MX2024007870A (es) 2021-12-23 2024-08-15 Flagship Pioneering Innovations Vi Llc Polirribonucleotidos circulares que codifican polipeptidos antifusogenicos.
US20250295687A1 (en) 2022-05-09 2025-09-25 Flagship Pioneering Innovations Vi, Llc Trem compositions and methods of use for treating proliferative disorders
TW202409283A (zh) 2022-05-13 2024-03-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 雙股ｄｎａ組合物及相關方法
JP2025517967A (ja) 2022-05-25 2025-06-12 フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー サイトカインを調節するための組成物及び方法
EP4532768A2 (en) 2022-05-25 2025-04-09 Flagship Pioneering Innovations VII, LLC Compositions and methods for modulating circulating factors
CA3254044A1 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc COMPOSITIONS AND MODULATION METHODS OF TUMOR SUPPRESSANTS AND ONCOGENS
CN119563038A (zh) 2022-05-25 2025-03-04 旗舰创业创新七公司 用于调节免疫应答的组合物和方法
WO2023230570A2 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulating genetic drivers
WO2023250112A1 (en) 2022-06-22 2023-12-28 Flagship Pioneering Innovations Vi, Llc Compositions of modified trems and uses thereof
CN115368462B (zh) * 2022-07-19 2026-01-02 合肥天港免疫药物有限公司 双特异性抗体及其应用
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
EP4612296A1 (en) 2022-10-31 2025-09-10 Flagship Pioneering Innovations VI, LLC Compositions and methods for purifying polyribonucleotides
WO2024097859A1 (en) * 2022-11-03 2024-05-10 Board Of Regents, The University Of Texas System An adjuvant and cd47-blockade combination cancer treatment and methods of using the same
TW202434728A (zh) 2022-11-08 2024-09-01 美商旗艦先鋒創新有限責任公司 用於產生環狀多核糖核苷酸的組成物和方法
WO2024129988A1 (en) 2022-12-14 2024-06-20 Flagship Pioneering Innovations Vii, Llc Compositions and methods for delivery of therapeutic agents to bone
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024151685A1 (en) 2023-01-09 2024-07-18 Beth Israel Deaconess Medical Center, Inc. Recombinant nucleic acid molecules and their use in wound healing
WO2024151673A2 (en) 2023-01-09 2024-07-18 President And Fellows Of Harvard College Recombinant nucleic acid molecules and their use in wound healing
AU2024222598A1 (en) 2023-02-17 2025-07-31 Flagship Pioneering Innovations Vii, Llc Dna compositions comprising modified uracil
JP2026507514A (ja) 2023-02-17 2026-03-04 フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー 修飾されたシトシンを含むｄｎａ組成物
WO2024192422A1 (en) 2023-03-15 2024-09-19 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and uses thereof
AU2024235803A1 (en) 2023-03-15 2025-09-25 Flagship Pioneering Innovations Vi, Llc Compositions comprising polyribonucleotides and uses thereof
EP4695391A1 (en) 2023-04-12 2026-02-18 Flagship Pioneering Innovations VI, LLC Trems for use in correction of missense mutations
WO2025006684A1 (en) 2023-06-28 2025-01-02 Flagship Pioneering Innovations Vi, Llc Circular polyribonucleotides encoding antifusogenic polypeptides
WO2025042786A1 (en) 2023-08-18 2025-02-27 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides and uses thereof
WO2025096807A2 (en) 2023-10-31 2025-05-08 Flagship Pioneering Innovations Vii, Llc Novel therapeutic dna forms
US20260000702A1 (en) 2024-06-26 2026-01-01 Flagship Pioneering Innovations Vii, Llc Therapeutic circular dna forms
WO2026055547A1 (en) 2024-09-06 2026-03-12 Flagship Pioneering Innovations Vii, Llc Dna compositions and related methods
WO2026055543A1 (en) 2024-09-06 2026-03-12 Flagship Pioneering Innovations Vii, Llc Modified dna compositions and related methods
WO2026064313A1 (en) 2024-09-17 2026-03-26 Flagship Pioneering Innovations Vii, Llc Rna compositions and related methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9605709D0 (en) * 1996-03-19 1996-05-22 Cortecs Ltd Method
US20040229335A1 (en) * 2003-05-15 2004-11-18 Introgen Therapeutics, Inc. Methods and compositions for the production of adenoviral vectors
FR2925339B1 (fr) * 2007-12-24 2010-03-05 Erytech Pharma Medicament pour le traitement du cancer du pancreas
US20100040546A1 (en) * 2008-08-13 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Biological targeting compositions and methods of using the same
US8461311B2 (en) * 2010-06-08 2013-06-11 Washington University TRAIL trimers, methods and uses therefor
EP2994530A4 (en) 2013-05-10 2016-11-16 Whitehead Biomedical Inst PROTEIN MODIFYING LIVING CELLS USING SORTASE
HK1222662A1 (zh) 2013-05-10 2017-07-07 Whitehead Institute For Biomedical Research 体外生产具有可分选蛋白的无核红细胞
EP3071515A2 (en) * 2013-11-18 2016-09-28 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
EP3583946A1 (en) 2014-04-01 2019-12-25 Rubius Therapeutics, Inc. Enucleated hematopoietic cells comprising an exogenous antigen

Similar Documents

Publication Publication Date Title
Shen et al. Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives
Tie et al. Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets
Jacquelot et al. Tertiary lymphoid structures and B lymphocytes in cancer prognosis and response to immunotherapies
Amatore et al. Role of Inducible Co-Stimulator (ICOS) in cancer immunotherapy
Rüter et al. Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors
Fournier et al. Trial watch: adoptively transferred cells for anticancer immunotherapy
Ishikawa et al. Phase I clinical trial of adoptive transfer of expanded natural killer cells in combination with I g G 1 antibody in patients with gastric or colorectal cancer
Cauwels et al. Delivering type I interferon to dendritic cells empowers tumor eradication and immune combination treatments
West et al. PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells
Aspord et al. Plasmacytoid dendritic cells support melanoma progression by promoting Th2 and regulatory immunity through OX40L and ICOSL
Comin-Anduix et al. Tremelimumab: research and clinical development
Wang et al. What happens to the immune microenvironment after PD-1 inhibitor therapy?
Draghiciu et al. Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication
JP2025148404A (ja) Ｔ細胞療法のために患者をコンディショニングする方法
Placke et al. GITR ligand provided by thrombopoietic cells inhibits NK cell antitumor activity
Suzuki et al. Current status of immunotherapy
Dömling et al. Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapy
Darcy et al. Manipulating immune cells for adoptive immunotherapy of cancer
Tabana et al. Reversing T-cell exhaustion in immunotherapy: a review on current approaches and limitations
Hu et al. The effects of chemotherapeutic drugs on human monocyte-derived dendritic cell differentiation and antigen presentation
Sierra et al. Tumor-experienced human NK cells express high levels of PD-L1 and inhibit CD8+ T cell proliferation
Ju et al. Administration of 6‐gingerol greatly enhances the number of tumor‐infiltrating lymphocytes in murine tumors
Schirdewahn et al. The third signal cytokine IL-12 rather than immune checkpoint inhibitors contribute to the functional restoration of hepatitis D virus-specific T-cells
CN104114233A (zh) 转换共刺激受体
Wang et al. Radiotherapy as a new player in immuno-oncology